Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-6.82%
+2.63%
+16.42%
+10.84%
+2.79%
Top.GainersTop.Gainers highlighting the top gainers of the day, providing timely updates and insights on the market's highest achievers.
18 Feb 2026$IBRX surged 41.86% to $8.54 on Wednesday after ImmunityBio announced that the European Commission granted conditional marketing authorization for ANKTIVA in combination with Bacillus Calmette-Guérin. Investor enthusiasm reflects the potential commercial opportunity for this immunotherapy, pushing trading volume sharply above its average 42.27M shares and signaling strong momentum for biotech watchers.
$AUUD jumped 36.56% to $1.14 following the announcement of a definitive merger agreement with Thramann Holdings, set to restructure into a new entity named McCarthy Finney. The deal, which grants existing shareholders roughly 20% ownership of the combined company, has sparked speculative interest as the market prices in strategic growth potential and anticipated synergies. Pre-market volume soared to 102.73M, vastly above the average 713K, reflecting aggressive buying activity.
$SABR climbed 24.68% to $1.17 after reporting a narrower-than-expected Q4 loss, with revenues rising 3% year-over-year driven by stronger air bookings. The earnings beat both top-line and bottom-line estimates, providing confidence in operational recovery. Volume expanded to 30.8M compared with a 7.46M average, indicating that traders are responding to the improved fundamentals with significant positioning.
$APRE advanced 21.33% to $0.73 as Aprea Therapeutics disclosed additional positive clinical activity from its ongoing Phase 1 ACESOT-1051 trial for the WEE1 inhibitor APR-1051, including a second partial response in a patient with advanced endometrial cancer. The early-stage clinical success is fueling optimism around the drug potential, though trading remains relatively moderate with volume just above its 4.09M average.
$HYMC rose 21.07% to $40.68 after Hycroft Mining reported 55% growth in mineral resources, highlighting substantial increases in gold and silver reserves with strong recoveries in metallurgy tests. Investor focus on the robust resource expansion has pushed volume to 6.21M versus the 5.34M average, indicating steady accumulation by commodity-focused traders.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 5,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
FIND US ON
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
